Hematologic Oncology

The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.

FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.

Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

Robert Stuver, MD, discusses how to approach treatment for primary cutaneous peripheral T-cell lymphoma and which factors to consider.

H. Miles Prince, MD, MBBS discusses data for mogamulizumab from MAVORIC vs real-world vorinostat in R/R MF and SS.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

From CD94 antibodies to TNF-α and EZH2, Neha Mehta-Shah, MD, MSCI, explains how a wave of newly mapped targets is reshaping cutaneous T-cell lymphoma.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.